

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Other				
Adjuvant	Not applicable	<p><i>In vitro</i> and mouse studies suggest modified K-class CpG oligodeoxynucleotides (K-ODNs) could be useful as vaccine adjuvants. In mice vaccinated against foot and mouth disease, a modified K-ODN nanoring adjuvant induced a stronger T helper type 1 (Th1) immune response than unmodified K-ODN or K-ODN mixed with a human peptide. In mice receiving a tumor vaccine, the K-ODN nanoring adjuvant induced a more potent antitumor response than unmodified K-ODN. Next steps include testing the adjuvants in primate models.</p> <p>SciBX 7(23); doi:10.1038/scibx.2014.683 Published online June 12, 2014</p>	Patent status available from principal investigator; available for licensing	<p>Gungor, B. <i>et al. Sci. Transl. Med.</i>; published online May 7, 2014; doi:10.1126/scitranslmed.3007909 Contact: Mayda Gursel, Middle East Technical University, Ankara, Turkey e-mail: mgursel@metu.edu.tr</p>